keyword
MENU ▼
Read by QxMD icon Read
search

hbv hcv coinfection

keyword
https://www.readbyqxmd.com/read/29901821/risk-of-diabetes-in-hiv-infected-patients-is-associated-with-cirrhosis-but-not-with-chronic-hcv-coinfection-in-a-french-nationwide-hiv-cohort
#1
A Provoost, M Dramé, L Cotte, L Cuzin, R Garraffo, D Rey, F Raffi, I Poizot-Martin, P Pugliese, F Bani-Sadr
BACKGROUND: Both human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections have been reportedly associated with a higher risk of diabetes mellitus (DM) but results are conflicting. AIMS: To determine whether there is an association between chronic HCV and the incidence of DM, and to study the role of factors such as cirrhosis, IFN-based HCV therapy, sustained virologic response (SVR) and chronic HBV infection among patients living with HIV (PLHIV) followed in a large French multicentre cohort in the combination antiretroviral therapy (cART) era...
June 14, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29844604/hiv-reverse-transcriptase-and-protease-genes-variability-can-be-a-biomarker-associated-with-hiv-and-hepatitis-b-or-c-coinfection
#2
Natália Mirele Cantão, Lauana Fogaça de Almeida, Ivan Rodrigo Wolf, Rodrigo Oliveira Almeida, Andressa Alves de Almeida Cruz, Caroline Nunes, Alexandre Naime Barbosa, Guilherme Targino Valente, Maria Inês de Moura Campos Pardini, Rejane Maria Tommasini Grotto
Variability of the HIV reverse transcriptase (RT) and protease (PR) genes has been used as indicators of drug resistance and as a mean to evaluate phylogenetic relationships among circulating virus. However, these studies have been carried in HIV mono-infected populations. The goal of this study was to evaluate, for the first time, the HIV PR and RT sequences from HIV/HBV and HIV/HCV co-infected patients. HIV PR and RT genes were amplificated and sequenced to resistance analysis. The bioinformatics analysis was performed to infer about sequences clustering and molecular evolution...
May 29, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29793873/executive-summary-of-the-gesida-consensus-document-on-control-and-monitoring-of-hiv-infected-patients
#3
(no author information available yet)
The continuous increase in our knowledge of HIV medicine and antiretroviral treatment has led us to draft specific consensus documents focused on topics other than antiretroviral therapy, such as treatment of opportunistic diseases, pre- and post-exposure prophylaxis, metabolic abnormalities, treatment of HBV or HCV coinfection, treatment of patients coinfected with tuberculosis, osteoporosis, kidney disorders, and cardiovascular risk. Accordingly, the AIDS Study Group (GeSIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology has promoted the drafting of this consensus document on the control and monitoring of adult patients infected with HIV...
May 21, 2018: Enfermedades Infecciosas y Microbiología Clínica
https://www.readbyqxmd.com/read/29785877/hepatitis-b-virus-lymphotropism-emerging-details-and-challenges
#4
Shivali S Joshi, Carla S Coffin
The hepatitis B virus (HBV) is predominantly a hepatotropic virus but also infects cells of the lymphatic system. HBV genomes (DNA, messenger (m)RNA, covalently closed circular (ccc) DNA) and proteins have been found in extrahepatic sites such as peripheral blood mononuclear cells (PBMC), lymph nodes, spleen, bone marrow and cerebrospinal fluid. HBV entry into hepatocytes occurs by binding of the HBV preS1 surface protein to its specific receptor, the bile acid transporter, sodium taurocholate co-transporting polypeptide (NTCP)...
May 22, 2018: Biotechnology & Genetic Engineering Reviews
https://www.readbyqxmd.com/read/29761585/hepatitis-b-virus-hbv-reactivation-the-potential-role-of-direct-acting-agents-for-hepatitis-c-virus-hcv
#5
REVIEW
Jason T Blackard, Kenneth E Sherman
Hepatitis C virus (HCV) is known to inhibit hepatitis B virus (HBV) replication in patients with HBV/HCV coinfection. Reactivation of HBV in patients treated for HCV with direct-acting agents (DAAs) has emerged recently as an important clinical consideration. A growing number of case reports and case series support the association between new HCV treatments and HBV reactivation. Yet, very little is known about the specific viral characteristics that facilitate reactivation as functional characterization of the reactivated HBV has been conducted only rarely...
May 15, 2018: Reviews in Medical Virology
https://www.readbyqxmd.com/read/29759421/prevalence-and-distribution-of-hepatitis-c-virus-genotypes-in-galicia-during-the-period-2000-2015
#6
Daniel Navarro-de la Cruz, Sonia Pérez-Castro, Matilde Trigo-Daporta, Antonio Aguilera-Guirao
INTRODUCTION: We present the largest study conducted in Galicia on the prevalence and distribution of HCV genotypes/subtypes. METHODS: Retrospective study collecting the total number of patients chronically infected by HCV between 2000.01.01 to 2015.12.31 in 3of the main health areas: Santiago, Pontevedra and Vigo. RESULTS: We collected a total of 4469 patients. The median age was 50 years (IQR 57-45), 72,3% were men, 0,4% were coinfected with another genotype, 20,6% were coinfected with HIV and 35...
May 11, 2018: Enfermedades Infecciosas y Microbiología Clínica
https://www.readbyqxmd.com/read/29742524/prevalence-and-incidence-of-hepatitis-delta-in-patients-with-chronic-hepatitis-b-in-spain
#7
Antonio Aguilera, Rocio Trastoy, Javier Rodríguez-Calviño, Tamara Manso, Carmen de Mendoza, Vicente Soriano
BACKGROUND: Hepatitis delta virus (HDV) is a defective agent that only replicates in the presence of the hepatitis B virus. Accordingly, HDV acquisition may occur as superinfection of HBsAg+ carriers or following acute dual HDV and hepatitis B virus exposure. Herein, we examined the global and incident rates of HDV infections in Spain. PATIENTS AND METHODS: The presence of anti-HDV antibody and new HDV superinfections was examined in all HBsAg+ patients who attended one large tertiary outclinic in Spain since year 2000...
May 8, 2018: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29720863/hepatitis-b-and-c-coinfection-in-a-real-life-setting-viral-interactions-and-treatment-issues
#8
Nikolaos Papadopoulos, Maria Papavdi, Anna Pavlidou, Dimitris Konstantinou, Hariklia Kranidioti, George Kontos, John Koskinas, George V Papatheodoridis, Spilios Manolakopoulos, Melanie Deutsch
Background: Only limited data concerning hepatitis B (HBV) and C viruses (HCV) coinfection are available. Direct-acting antivirals (DAAs) may be more effective for HCV clearance than interferon (IFN)-based regimens with a risk of HBV reactivation. Methods: We retrospectively enrolled 40 HBV/HCV-coinfected patients to evaluate their clinical profile and treatment outcomes. Results: Chronic dual infection was present in 25/40 (62.5%) patients, acute HCV superinfection in 5/40 (12...
May 2018: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/29692581/cluster-of-differentiation-4-t-cell-counts-and-human-immunodeficiency-virus-1-viral-load-in-patients-coinfected-with-hepatitis-b-virus-and-hepatitis-c-virus
#9
Sakshee Gupta, Bharti Malhotra, Jitendra Kumar Tiwari, Prabhu Dayal Khandelwal, Rakesh Kumar Maheshwari
BACKGROUND: Coinfections of human immunodeficiency virus (HIV) with hepatitis viruses may affect the progress of disease and response to therapy. OBJECTIVES: To study the incidence of hepatitis B virus (HBV) and hepatitis C virus (HCV) coinfections in HIV-positive patients and their influence on HIV-1 viral load and cluster of differentiation 4+ (CD4+) T-cell counts. MATERIALS AND METHODS: This pilot study was done on 179 HIV-positive patients attending antiretroviral therapy (ART) centre...
April 2018: Journal of Laboratory Physicians
https://www.readbyqxmd.com/read/29619424/liver-stiffness-measurement-predicted-liver-related-events-and-all-cause-mortality-a-systematic-review-and-nonlinear-dose-response-meta-analysis
#10
Junna Wang, Jiajun Li, Quan Zhou, Dandan Zhang, Qiu Bi, Yulin Wu, Wenxiang Huang
Numerous studies have investigated the prognosis value of the liver stiffness measurement (LSM) by transient elastography in assessing the risk of liver-related events (LREs) and all-cause mortality in patients with chronic liver disease (CLD). However, the shape of the dose-response relationship between them remains unclear. We searched PubMed, Embase, the Cochrane Library, and reference lists of articles for studies published up to July 1, 2017, that assessed the LSM in predicting LREs and all-cause mortality among subjects with CLD...
April 2018: Hepatology Communications
https://www.readbyqxmd.com/read/29595065/protease-inhibitor-therapy-for-hepatitis-c-virus-infection
#11
P de Leuw, C Stephan
The hepatitis C virus (HCV) has affected an estimated of 80 million individuals worldwide and is a strain on public health. Around 25-30% of patients in Europe and the US who are infected with HIV are coinfected with HCV. Prior to 2013, treatment modalities containing an NS3/4A protease inhibitor in combination with pegylated interferon and ribavirin improved sustained virological response (SVR) rates. However, rates of severe side effects were high. Nowadays, oral direct-acting antiviral (DAA) combination therapy offers excellent treatment efficacy, safety and tolerability...
April 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29577515/impact-of-previous-hepatitis-b-infection-on-the-clinical-outcomes-from-chronic-hepatitis-c-a-population-level-analysis
#12
H Wang, R Swann, E Thomas, H A Innes, H Valerio, P C Hayes, S Allen, S T Barclay, D Wilks, R Fox, D Bhattacharyya, N Kennedy, J Morris, A Fraser, A J Stanley, R Gunson, P G Mclntyre, A Hunt, S J Hutchinson, P R Mills, J F Dillon
Chronic coinfection with hepatitis C virus (HCV) and hepatitis B virus (HBV) is associated with adverse liver outcomes. The clinical impact of previous HBV infection on liver disease in HCV infection is unknown. We aimed at determining any association of previous HBV infection with liver outcomes using antibodies to the hepatitis B core antigen (HBcAb) positivity as a marker of exposure. The Scottish Hepatitis C Clinical Database containing data for all patients attending HCV clinics in participating health boards was linked to the HBV diagnostic registry and mortality data from Information Services Division, Scotland...
March 25, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29532619/effect-of-hepatitis-b-virus-on-steatosis-in-hepatitis-c-virus-co-infected-subjects-a-multi-centre-study-and-systematic-review
#13
N Goossens, C de Vito, A Mangia, S Clément, G Cenderello, F Barrera, R D'Ambrosio, N Coppola, R Zampino, M Stanzione, L E Adinolfi, H Wedemeyer, N Semmo, B Müllhaupt, D Semela, R Malinverni, D Moradpour, M Heim, G Trincucci, L Rubbia-Brandt, F Negro
It remains unclear whether hepatitis B virus (HBV) infection may modify the severity of viral steatosis in patients coinfected with chronic hepatitis C virus (HCV). We examined the influence of coinfection with HBV on prevalence of steatosis in chronic hepatitis C in a multi-centre cohort of HBV-HCV subjects, and by performing a systematic review and meta-analysis of the literature. We centrally and blindly assessed steatosis prevalence and severity in a cohort of HBV-HCV coinfected subjects compared to HCV and HBV monoinfected controls and we performed a systematic review of studies addressing the prevalence of steatosis in HBV-HCV subjects compared to HCV controls...
March 13, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29487874/epidemiological-profile-and-risk-factors-for-acquiring-hbv-and-or-hcv-in-hiv-infected-population-groups-in-nepal
#14
Manjula Bhattarai, Jagat Bahadur Baniya, Nirmal Aryal, Bimal Shrestha, Ramanuj Rauniyar, Anurag Adhikari, Pratik Koirala, Pardip Kumar Oli, Ram Deo Pandit, David A Stein, Birendra Prasad Gupta
HBV and HCV infections are widespread among the HIV-infected individuals in Nepal. The goals of this study were to investigate the epidemiological profile and risk factors for acquiring HBV and/or HCV coinfection in disadvantaged HIV-positive population groups in Nepal. We conducted a retrospective study on blood samples from HIV-positive patients from the National Public Health Laboratory at Kathmandu to assay for HBsAg, HBeAg, and anti-HCV antibodies, HIV viral load, and CD4+ T cell count. Among 579 subjects, the prevalence of HIV-HBV, HIV-HCV, and HIV-HBV-HCV coinfections was 3...
2018: BioMed Research International
https://www.readbyqxmd.com/read/29434450/incidence-of-hepatocellular-carcinoma-in-patients-with-chronic-liver-disease-due-to-hepatitis-b-or-c-and-coinfected-with-the-human-immunodeficiency-virus-a-retrospective-cohort-study
#15
Patrícia Dos Santos Marcon, Cristiane Valle Tovo, Dimas Alexandre Kliemann, Patrícia Fisch, Angelo Alves de Mattos
AIM: To assess the incidence of hepatocellular carcinoma (HCC) in chronic liver disease due to hepatitis B virus (HBV) or hepatitis C virus (HCV) coinfected with human immunodeficiency virus (HIV). METHODS: A retrospective cohort study was performed, including patients with chronic liver disease due to HBV or HCV, with and without HIV coinfection. Patients were selected in the largest tertiary public hospital complex in southern Brazil between January 2007 and June 2014...
February 7, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29404490/survival-following-hospitalization-with-hepatocellular-carcinoma-among-people-notified-with-hepatitis-b-or-c-virus-in-australia-2000-2014
#16
Reem Waziry, Jason Grebely, Janaki Amin, Maryam Alavi, Behzad Hajarizadeh, Jacob George, Gail V Matthews, Matthew Law, Gregory J Dore
We assessed trends in HCC survival in patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection in New South Wales, Australia. Data on HBV (n = 54,399) and HCV (n = 96,908) notifications (1993-2012) were linked to a hospitalization database (July 2000-June 2014), the New South Wales Cancer Registry, and the New South Wales Death Registry. A total of 725 (1.3%) first HBV-hepatocellular carcinoma (HCC) and 1,309 (1.4%) first HCV-HCC hospitalizations were included. Death occurred in 60.4% of HBV-HCC and 69...
October 2017: Hepatology Communications
https://www.readbyqxmd.com/read/29397016/risk-of-hepatitis-b-virus-reactivation-in-hepatitis-b-virus-hepatitis-c-virus-co-infected-patients-with-compensated-liver-cirrhosis-treated-with-ombitasvir-paritaprevir-r-dasabuvir-ribavirin
#17
C M Preda, C P Popescu, C Baicus, I Constantinescu, A Oproiu, T Voiosu, M Diculescu, L Negreanu, L Gheorghe, I Sporea, A Trifan, E Ceausu, D Proca, M Manuc
Hepatitis B virus may reactivate in patients with chronic hepatitis C treated with direct-acting antivirals. The aim of this study was to investigate the risk of hepatitis B virus (HBV) reactivation in HBV + hepatitis C virus (HCV)-co-infected patients with compensated liver cirrhosis treated with paritaprevir/ombitasvir/ritonavir, dasabuvir with ribavirin. We reviewed prospectively gathered data from a national cohort of 2070 hepatitis C virus patients with compensated liver cirrhosis who received reimbursed paritaprevir/ombitasvir/r, dasabuvir with ribavirin for 12 weeks from the Romanian National Health Agency during 2015-2016...
February 3, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29371017/hepatitis-b-virus-reactivation-during-direct-acting-antiviral-therapy-for-hepatitis-c-a-systematic-review-and-meta-analysis
#18
Marcus M Mücke, Lisa I Backus, Victoria T Mücke, Nicola Coppola, Carmen M Preda, Ming-Lun Yeh, Lydia S Y Tang, Pamela S Belperio, Eleanor M Wilson, Ming-Lung Yu, Stefan Zeuzem, Eva Herrmann, Johannes Vermehren
BACKGROUND: Direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection might pose a risk for hepatitis B virus (HBV) reactivation in patients coinfected with chronic or resolved HBV infection. The need for HBV antiviral prophylaxis during DAA treatment remains controversial. We aimed to analyse the absolute risk of HBV reactivation in patients with active or resolved HBV infection treated with DAAs for HCV infection. METHODS: For this systematic review and meta-analysis, we searched PubMed, Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and Web of Science from Oct 1, 2010, to Sept 30, 2017, to identify studies of patients with chronic or resolved HBV infection at baseline treated with DAAs for chronic HCV infection...
January 19, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29369303/report-from-the-international-conference-on-viral-hepatitis-2017
#19
Vicente Soriano, Benjamin Young, Nancy Reau
The International Conference on Viral Hepatitis 2017 brought exciting news on the treatment of viral hepatitis. The most recent estimates of the burden for hepatitis B virus and hepatitis C virus (HCV) infections were presented. The current gaps and prospects for regional and global eradication of viral hepatitis were discussed on the light of the WHO roadmap until 2030. Debates focused on hepatitis C and expectations using the new approved HCV pan-genotypic, once daily, oral direct-acting antivirals (DAAs), glecaprevir-pibrentasvir, and sofosbuvir-velpatasvir-voxilaprevir...
January 2018: AIDS Reviews
https://www.readbyqxmd.com/read/29322398/hepatitis-c-virus-infection-and-development-of-type-2-diabetes-mellitus-systematic-review-and-meta-analysis-of-the-literature
#20
REVIEW
Silvia Fabiani, Poupak Fallahi, Silvia Martina Ferrari, Mario Miccoli, Alessandro Antonelli
Type 2 diabetes mellitus (T2DM) is an endocrine disorder encompassing multifactorial mechanisms, and chronic hepatitis C virus infection (CHC) is a multifaceted disorder, associated with extrahepatic manifestations, including endocrinological disorders. CHC and T2DM are associated, but the subject remains controversial. We performed a systematic review and meta-analysis evaluating such association, searching on PubMed until February 29, 2016. Inclusion criteria were: 1) presence of at least one internal control group age- and gender-matched (non-hepatopathic controls; and/or hepatopathic, not HCV-positive, controls); 2) sufficient data to calculate odds ratio and relative risk...
January 11, 2018: Reviews in Endocrine & Metabolic Disorders
keyword
keyword
100245
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"